Sunday, April 09, 2023 12:23:43 AM
Cancer and heart disease vaccines ‘ready by end of the decade:
Dr Paul Burton, the chief medical officer of pharmaceutical company Moderna, said he believes the firm will be able to offer such treatments for “all sorts of disease areas” in as little as five years.
https://www.theguardian.com/society/2023/apr/07/cancer-and-heart-disease-vaccines-ready-by-end-of-the-decade
Dr Paul Burton, the chief medical officer of pharmaceutical company Moderna, said he believes the firm will be able to offer such treatments for “all sorts of disease areas” in as little as five years.
https://www.theguardian.com/society/2023/apr/07/cancer-and-heart-disease-vaccines-ready-by-end-of-the-decade
Recent MRNA News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2026 09:13:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2026 09:10:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/29/2026 09:04:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/18/2026 08:57:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/15/2026 01:47:23 PM
- Moderna Recognized by TIME as One of the World's Most Impactful Companies • ACCESS Newswire • 05/12/2026 09:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Moderna (MRNA) Shares Surge After U.S. Passenger Tests Positive for Hantavirus • IH Market News • 05/11/2026 10:38:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 10:06:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 09:06:08 PM
- Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 • ACCESS Newswire • 05/06/2026 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/04/2026 09:25:09 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/01/2026 08:10:14 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/01/2026 03:44:50 PM
- Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates • ACCESS Newswire • 05/01/2026 10:30:00 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 03:30:03 PM
- Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate • ACCESS Newswire • 04/21/2026 11:01:00 PM
- Moderna Announces Data to be Presented at 2026 ASCO Annual Meeting • ACCESS Newswire • 04/21/2026 02:00:00 PM
- Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19 • ACCESS Newswire • 04/21/2026 01:40:00 PM
- Moderna to Present at Upcoming Conferences in May 2026 • ACCESS Newswire • 04/21/2026 11:00:00 AM
- Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026 AACR Annual Meeting • ACCESS Newswire • 04/17/2026 07:00:00 PM
- Moderna to Report First Quarter 2026 Financial Results on Friday, May 1, 2026 • ACCESS Newswire • 04/15/2026 11:00:00 AM
- Moderna to Present Revaccination Data for Its Investigational Seasonal Influenza Vaccine and for mRESVIA at ESCMID 2026 • ACCESS Newswire • 04/06/2026 10:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 08:45:51 PM
